Alto Neuroscience elevates CFO Nicholas Smith to president role
The company also put in place a two-year retention package worth $6 million tied to Smith staying through August 2028.
SEC filing
Latest
5 stories
Thursday, August 27
Wednesday, August 12
Alto Neuroscience adds third Phase 3 trial for ALTO-207, cites Nature Medicine data
Company now plans a monotherapy trial alongside its adjunctive Phase 3 study in treatment-resistant depression, backed by roughly $338 million in pro forma cash.
SEC filing
Tuesday, July 14
Alto Neuroscience prices $93.9 million stock offering to fund ALTO-207 trial
The company will use proceeds to expand development of ALTO-207 for treatment-resistant depression, including an additional Phase 3 trial.
SEC filing
Alto Neuroscience prices $100 million offering, plans Phase 3 trial of ALTO-207
The company priced 3,776,436 shares at $26.48 each and will direct proceeds toward an additional Phase 3 trial of ALTO-207 for treatment resistant depression.
SEC filing
Monday, July 13
Alto Neuroscience plans added Phase 3 trial for depression drug ALTO-207
The company disclosed plans to expand development of ALTO-207 alongside a preliminary cash update as of June 30, 2026.
SEC filing